PMID- 24740470
OWN - NLM
STAT- Publisher
LR  - 20191120
IS  - 1542-6270 (Electronic)
IS  - 1060-0280 (Linking)
VI  - 48
IP  - 7
DP  - 2014 Jul
TI  - Colesevelam, Ezetimibe, and Patients With Type 2 Diabetes Mellitus: 
      Characteristics and Clinical Outcomes From a Health Care Database.
PG  - 847-855
AB  - BACKGROUND: Despite the prevalence of therapies available to patients at highest 
      coronary heart disease risk, only a minority of type 2 diabetes mellitus (T2DM) 
      patients reach desired cholesterol treatment levels, with limited data regarding 
      their outcomes. OBJECTIVE: To examine "real-world" effectiveness of initiating 
      treatment with either colesevelam or ezetimibe among individuals with evidence of 
      T2DM and hypercholesterolemia (HCh). Key outcomes included treatment patterns and 
      cardiovascular (CV) events. METHODS: This retrospective administrative 
      claims-based study utilized medical, pharmacy, and enrollment data linked to 
      laboratory results information from a large United States health plan (January 1, 
      2006, to March 31, 2011) and included individuals with recorded evidence of T2DM 
      and HCh. The index date was the date of first pharmacy claim for colesevelam or 
      ezetimibe, with cohort assignment based on index medication. Assessments included 
      baseline characteristics, follow-up treatment patterns, and composite CV event, 
      with propensity score matching to correct for sample selection bias. RESULTS: In 
      total, 4231 individuals were identified with evidence of HCh and T2DM (ezetimibe 
      n = 3384; colesevelam n = 847). After matching, the baseline characteristics 
      between cohorts were rendered to be similar. Mean days of persistent medication 
      use was lower with colesevelam compared with ezetimibe (P < 0.001). Compared with 
      ezetimibe, a smaller percentage of individuals in the colesevelam cohort 
      experienced a follow-up composite CV event, and adjusted Cox model results 
      suggested decreased risk (hazard ratio = 0.58; P = 0.004) of a follow-up 
      composite CV event. CONCLUSION: In this health care database analysis among 
      patients with HCh and T2DM, colesevelam was associated with decreased risk of a 
      composite CV event compared with ezetimibe, despite lower persistence.
CI  - (c) The Author(s) 2014.
FAU - Swindle, Jason P
AU  - Swindle JP
AD  - Optum, Inc, Eden Prairie, MN, USA jason.swindle@optum.com.
FAU - Ye, Xin
AU  - Ye X
AD  - Daiichi Sankyo, Inc, Parsippany, NJ, USA.
FAU - Mallick, Rajiv
AU  - Mallick R
AD  - Formerly of Daiichi Sankyo, Inc, Parsippany, NJ, USA.
FAU - Song, Rui
AU  - Song R
AD  - Optum, Inc, Eden Prairie, MN, USA.
FAU - Horstman, Thomas
AU  - Horstman T
AD  - Optum, Inc, Eden Prairie, MN, USA.
FAU - Bays, Harold E
AU  - Bays HE
AD  - L-Marc Research Center, Louisville, KY, USA.
LA  - eng
PT  - Journal Article
DEP - 20140416
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
OTO - NOTNLM
OT  - adherence
OT  - cardiovascular
OT  - colesevelam
OT  - diabetes
OT  - ezetimibe
OT  - persistence
EDAT- 2014/04/18 06:00
MHDA- 2014/04/18 06:00
CRDT- 2014/04/18 06:00
PHST- 2014/04/18 06:00 [entrez]
PHST- 2014/04/18 06:00 [pubmed]
PHST- 2014/04/18 06:00 [medline]
AID - 1060028014531737 [pii]
AID - 10.1177/1060028014531737 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2014 Jul;48(7):847-855. doi: 10.1177/1060028014531737. Epub 
      2014 Apr 16.